SuperworthTrupanion TRUP
- Market cap
- $1.3B
- PE
- 55.3×
- 1y median 60.0×
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- 0.8×
- EV/EBIT
- 39.4×
- Revenue, 12 months
- $1.5B
- +12% on a year ago
- Net margin
- 1.5%
- Free cash flow yield
- 6.4%
Trupanion trades at 55.3× trailing earnings, near its ten-year median. Revenue was $1.5B over the last twelve months, up 12% on a year earlier with a 2% net margin.
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $285.9M+22% | $295.9M+20% | $306.1M+19% | $314.8M+16% | $327.5M+15% | $337.3M+14% | $342M+12% | $353.6M+12% | $366.9M+12% | $376.9M+12% | $384M+12% | $392.9M+11% | |
| Cost of revenue | $250.6M+23% | $255.8M+21% | $269.9M+17% | $274.5M+14% | $278.1M+11% | $284.4M+11% | $290.9M+8% | $298.7M+9% | $306.9M+10% | $311.8M+10% | $322.6M+11% | $327.8M+10% |
| Gross profit | $35.2M+17% | $40.1M+19% | $36.2M+38% | $40.3M+37% | $49.4M+40% | $52.9M+32% | $51.1M+41% | $54.8M+36% | $60.1M+22% | $65M+23% | $61.5M+20% | $65.1M+19% |
| R&D | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| SG&A | $30.4M−7% | $30.6M−7% | $31.5M−26% | $33.1M−2% | $35.3M+16% | $35.2M+15% | $40.4M+28% | $40M+21% | $40.3M+14% | $41.4M+18% | $41.7M+3% | $42.3M+6% |
| −$3.5M−71% | $408K | −$6.1M−75% | −$5.5M−58% | $1.7M | $348K−15% | −$1.5M−76% | $2.3M | $5.9M+236% | $7.1M+1951% | $4.8M | $6.4M+176% | |
| Interest expense | $3.1M+117% | $3.7M+133% | $3.6M+51% | $3.7M+24% | $3.8M+25% | $3.4M−7% | $3.2M−11% | $3.7M+1% | $2.8M−27% | $4.1M+19% | $1.9M−42% | $1.8M−50% |
| Pre-tax income | −$4.1M−67% | −$2M−78% | −$6.9M−72% | −$5.9M−58% | $1.5M | $1.7M | −$1.4M−79% | $10.5M | $6.6M+351% | $6.3M+272% | $6M | $7.4M−30% |
| −$43K | $130K | −$38K−80% | −$44K−82% | $39K | $38K−71% | $39K | $1.1M | $726K+1762% | $663K+1645% | $1.1M+2659% | $542K−52% | |
| Net income | −$4M−69% | −$2.2M−77% | −$6.9M−72% | −$5.9M−57% | $1.4M | $1.7M | −$1.5M−78% | $9.4M | $5.9M+312% | $5.6M+240% | $4.9M | $6.8M−27% |
| −$0.10−69% | −$0.05−78% | −$0.16−73% | −$0.14−58% | $0.03 | $0.04 | −$0.03−81% | $0.22 | $0.13+333% | $0.13+225% | $0.11 | $0.16−27% | |
| 41.5M+2% | 41.7M+2% | 41.9M+2% | 42.1M+2% | 42.8M+3% | 42.4M+2% | 42.8M+2% | 43.3M+3% | 43.6M+2% | 43.6M+3% | 43.7M+2% | 43.8M+1% |
Revenue: Q1 FY13 and Q1 FY14: 6 months less the 3 months printed beside them.
Gross profit: Q1 FY13 and Q1 FY14: 6 months less the 3 months printed beside them. 23 periods, Q4 FY20 to Q2 FY26: not printed by the filing, worked out from its own lines.
R&D: Q1 FY13 and Q1 FY14: 6 months less the 3 months printed beside them.
SG&A: Q1 FY13 and Q1 FY14: 6 months less the 3 months printed beside them.
Operating income: Q1 FY13 and Q1 FY14: 6 months less the 3 months printed beside them.
Interest expense: Q1 FY13: 6 months less the 3 months printed beside them.
Pre-tax income: Q1 FY13: 6 months less the 3 months printed beside them.
Income tax: Q1 FY13: 6 months less the 3 months printed beside them.
Net income: Q1 FY13 and Q1 FY14: 6 months less the 3 months printed beside them. 50 periods, Q2 FY13 to Q2 FY26: not printed by the filing, worked out from its own lines.
EPS, diluted: 9 periods, Q1 FY13 to Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: Q1 FY13: share-days: the 6-month average less the second quarter's. 5 periods, Q4 FY13 to Q4 FY23: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days. Q4 FY24 and Q4 FY25: share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Healthcare nearest Trupanion's size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| TRUPTrupanion | $1.3B | 55.3× | 60.0× | 0.8× | +12% | 1.5% | |
| CDRECadre | $1.3B | 37.0× | 35.8× | 1.9× | +20% | 5.3% | |
| BVSBioventus | $1.3B | 19.4× | 27.2× | 2.2× | +3% | 9.4% | |
| USPHU S Physical Therapy | $1.3B | 101× | 42.1× | 1.6× | +11% | 4.0% | |
| OMEROmeros | $1.2B | 10.9× | 11.7× | n/m | n/m | n/m | |
| HLFHerbalife | $1.4B | 8.6× | 10.4× | 0.3× | +6% | 3.2% | |
| OMDAOmada Health | $1.2B | 316× | 341× | 3.7× | +48% | 1.4% | |
| PCRXPacira BioSciences | $1.5B | 104× | 65.6× | 1.9× | +6% | 2.0% | |
| ANABAnaptysbio | $1.5B | 10.7× | 100.0× | n/m | n/m | n/m | |
| STAAStaar Surgical | $1.1B | 323× | 143× | 3.3× | +51% | 1.1% | |
| PNTGPennant | $1.5B | 46.5× | 47.0× | 1.3× | +38% | 2.9% | |
| Peer median | $1.3B | 41.8× | 44.5× | 1.9× | +16% | 3.0% |
More on Trupanion
Each number over time
- PE ratio
- Price to sales ratio
- EV/EBIT
- Price to free cash flow
- Price to book ratio
- Market cap
- Revenue
- EPS
- Free cash flow
- Profit margin
- Shares outstanding
Where it ranks
- #5of 11Health insurers with the highest profit margins
- #6of 11Health insurers with the fastest revenue growth
- #10of 11Health insurers with the lowest price to sales ratio
- #10of 10Health insurers with the lowest EV/EBIT
Its groups
About
- Industry
- Medical - Healthcare Plans
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .